Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a deal valued at $2.9 billion, marking a significant expansion of Neurocrine's endocrinology and rare-disease portfolio. The acquisition centers on Soleno's lead asset, a treatment for Prader-Willi syndrome (PWS), a rare genetic disorder affecting approximately 10,000 people in the United States. PWS is characterized by relentless, compulsive hunger that can lead to severe obesity, diabetes, and life-threatening complications such as stomach rupture. This transaction represents the first approved treatment specifically targeting this condition. The deal highlights continued activity in the biotech sector, with major players seeking to bolster their pipelines through strategic acquisitions of innovative therapies.
Wire timeline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a deal valued at $2.9 billion, marking a significant expansion of Neurocrine's endocrinology and rare-disease portfolio. The acquisition centers on Soleno's lead asset, a treatment for Prader-Willi syndrome (PWS), a rare genetic disorder affecting approximately 10,000 people in the United States. PWS is characterized by relentless, compulsive hunger that can lead to severe obesity, diabetes, and life-threatening complications such as stomach rupture. This transaction represents the first approved treatment specifically targeting this condition. The deal highlights continued activity in the biotech sector, with major players seeking to bolster their pipelines through strategic acquisitions of innovative therapies.
WSJ.com: US Business